Theracryf Plc
TCF.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.03 | -0.05 | 0.08 |
| FCF Yield | -195.39% | -128.22% | -39.62% | -26.64% |
| EV / EBITDA | 0.44 | -0.09 | -1.04 | -1.62 |
| Quality | ||||
| ROIC | -38.05% | -133.78% | -76.67% | -29.79% |
| Gross Margin | 0.00% | 97.22% | 97.06% | 0.00% |
| Cash Conversion Ratio | 1.14 | 0.84 | 1.00 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | 31.59% | – |
| Free Cash Flow Growth | 20.99% | 25.66% | -57.24% | 12.56% |
| Safety | ||||
| Net Debt / EBITDA | 1.03 | 0.56 | 1.00 | 1.43 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -11.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -18.32 | -10,525.09 | -10,447.92 | -1,505.63 |